1. Home
  2. GEVO vs ALT Comparison

GEVO vs ALT Comparison

Compare GEVO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEVO
  • ALT
  • Stock Information
  • Founded
  • GEVO 2005
  • ALT 1997
  • Country
  • GEVO United States
  • ALT United States
  • Employees
  • GEVO N/A
  • ALT N/A
  • Industry
  • GEVO Major Chemicals
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GEVO Industrials
  • ALT Health Care
  • Exchange
  • GEVO Nasdaq
  • ALT Nasdaq
  • Market Cap
  • GEVO 418.4M
  • ALT 292.0M
  • IPO Year
  • GEVO 2011
  • ALT N/A
  • Fundamental
  • Price
  • GEVO $1.73
  • ALT $3.83
  • Analyst Decision
  • GEVO Buy
  • ALT Strong Buy
  • Analyst Count
  • GEVO 2
  • ALT 6
  • Target Price
  • GEVO $7.58
  • ALT $17.40
  • AVG Volume (30 Days)
  • GEVO 9.4M
  • ALT 3.0M
  • Earning Date
  • GEVO 08-11-2025
  • ALT 08-12-2025
  • Dividend Yield
  • GEVO N/A
  • ALT N/A
  • EPS Growth
  • GEVO N/A
  • ALT N/A
  • EPS
  • GEVO N/A
  • ALT N/A
  • Revenue
  • GEVO $80,187,000.00
  • ALT $20,000.00
  • Revenue This Year
  • GEVO $909.99
  • ALT N/A
  • Revenue Next Year
  • GEVO $22.37
  • ALT $761,880.20
  • P/E Ratio
  • GEVO N/A
  • ALT N/A
  • Revenue Growth
  • GEVO 341.75
  • ALT N/A
  • 52 Week Low
  • GEVO $0.67
  • ALT $2.90
  • 52 Week High
  • GEVO $3.39
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • GEVO 57.77
  • ALT 51.79
  • Support Level
  • GEVO $1.54
  • ALT $3.35
  • Resistance Level
  • GEVO $1.86
  • ALT $3.66
  • Average True Range (ATR)
  • GEVO 0.14
  • ALT 0.19
  • MACD
  • GEVO 0.01
  • ALT 0.07
  • Stochastic Oscillator
  • GEVO 31.15
  • ALT 86.18

About GEVO Gevo Inc.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: